IFNε and its role in KRAS-mutated lung cancer
Elucidate the role and mechanism of IFNε in Kras-driven lung tumorigenesis
['FUNDING_R21'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-11290858
Finding out whether the protein IFNε helps KRAS-mutated lung cancers grow, which could help people with that type of lung cancer.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-11290858 on ClinicalTrials.gov |
What this research studies
The research team will use lab-grown lung cancer cells, mouse models of KRAS-driven tumors, and analyses of human tumor tissue to study how IFNε works in the lung. They will compare tumors with different co-mutations (like LKB1 or TP53) to see if IFNε acts differently across subgroups. The team will change IFNε levels to observe effects on tumor growth, immune signals, and reactive oxygen species. Results aim to reveal whether targeting IFNε could become a new treatment approach or biomarker for KRAS-mutant lung cancer.
Who could benefit from this research
Good fit: People with non-small cell lung cancer whose tumors carry KRAS mutations, especially those with co-occurring LKB1 or TP53 changes, would be most relevant to this work.
Not a fit: Patients without KRAS-mutated lung cancer or those with unrelated cancer types are unlikely to see direct benefit from this research.
Why it matters
Potential benefit: If successful, this could identify IFNε as a new target or biomarker that leads to better treatments or prognosis for people with KRAS-mutant lung cancer.
How similar studies have performed: While conventional type I interferons are well-studied in cancer, IFNε is much less explored and early lab data suggest a potentially pro-tumor role, so this approach is fairly novel.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUO, YANXIANG — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: GUO, YANXIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents